Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Drug Profile

Research programme: nitric oxide-donating therapies for eye disorders - NicOx

Alternative Names: NCX 1021; NCX 1653; NCX 422; NCX 434; NCX 470; NCX 667

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator NicOx
  • Class Nitroso compounds; Pregnadienetriols
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Diabetic retinopathy; Glaucoma; Ocular hypertension

Most Recent Events

  • 21 Feb 2017 Pharmacodynamics data from preclinical studies in Glaucoma and Ocular hypertension released by Nicox
  • 24 Jan 2017 NicOx announces intention to submit IND for NCX 470 to US FDA in Q4 2017
  • 24 Jan 2017 Nicox announces a successful pre-IND meeting with the US FDA for finalisation of planned phase II study design for NCX 470
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top